Brain Cancer Awareness Month: 2022 Immunotherapy Research Updates May 3, 2022December 14, 2022 CRI Staff CRI Impact Grantee Robert Michael Angelo, MD, PhD, of Stanford University led the development of a new way to conduct in-depth analysis of the biology and spatial relationships of cells within brain tumors. By constructing TissueNet, a dataset for training models, and Mesmer, a deep-learning algorithm, Dr. Angelo’s tools might reveal new approaches to brain cancer immunotherapy. This May, for Brain Cancer Awareness Month, discover new research, new treatments, and progress for a future immune to cancers of the brain and nervous system. Brain Cancer Treatment Update At the CRI Virtual Immunotherapy Patient Summit last October, Dr. David Reardon of Dana-Farber Cancer Institute discussed new immunotherapies and combination therapies in clinical trials. Overcoming Neuro-Immune Dysfunction We spoke with CRI Lloyd J. Old STAR Dr. Peter Fecci at Duke University about how his research is uncovering brain cancer’s defensive tactics to reveal potential new treatment approaches. Brain Cancer Patient Story After her third brain surgery, Jeannine entered a clinical trial for a personalized dendritic cell vaccine, a type of immunotherapy. Meet Jeannine Brain Cancer Scientist Spotlight CRI-V Foundation CLIP Investigator Dr. Adilia Hormigo is using cutting-edge technologies to analyze the molecular mechanisms of the immuno-suppressive tumor microenvironment in glioblastoma. Read Glioblastoma Research Immunotherapy for Brain Cancer Cancers of the brain and nervous system are relatively rare but very serious. Immunotherapy is showing significant promise where other approaches have failed, including in glioblastoma. READ Brain Cancer UPDATE Find a Clinical Trial Help speed the development of potentially lifesaving drugs. Discover trials for which you or a loved one may be eligible with the CRI Immunotherapy Clinical Trial Finder. FIND A Cancer Clinical TRIAL Support Brain Cancer Research CRI-Thompson Family Foundation CLIP Investigator Robert M. Prins, PhD, of UCLA recently led a study that shows immune checkpoint therapy temporarily slows glioblastoma progression but fails to establish an effective anti-tumor microenvironment and appears to increase molecular interactions inhibiting long-term immune response. These insights will help scientists develop new strategies to create more effective immunotherapies in future. This Brain Cancer Awareness Month, support lifesaving cancer immunotherapy research. DONATE to brain cancer research Read more: Post navigation Melanoma Monday: 2022 Immunotherapy Research Updates Read Story Bladder Cancer Awareness Month: 2022 Immunotherapy Research Updates Read Story
